Group 1: Company Control Changes - Huibo Yuntong's controlling shareholder, Shenhui Holdings, through Shenhui Jinwu, plans to acquire a 32.0875% stake in Baode Computing, which will result in Shenhui Jinwu holding 22.0875% of Baode Computing and gaining control [1] Group 2: Performance Disclosure - Shanghai Pudong International Airport reported a passenger throughput of 7.9471 million in August, a year-on-year increase of 6.9% [2] - The total number of aircraft movements at Pudong International Airport was 49,800, reflecting a 3.49% year-on-year growth [2] - Hongqiao International Airport recorded 2.44 million aircraft movements, up 1.58% year-on-year, with a passenger throughput of 4.4515 million, increasing by 2.18% [2] Group 3: Shareholding Changes - Jianlong Micro-Nano announced that major shareholders Zhongzheng Kaiyuan and Renquan Venture Capital plan to reduce their holdings by up to 3%, equating to a maximum of 300,175.2 shares [3] - Pruis disclosed that its shareholder, Shanghai Guanyu Investment Development Co., intends to reduce its stake by up to 3%, which amounts to 237,010 shares [4] - Jiafa Education reported that its shareholder, Tibet Deyuantai Information Technology Co., plans to reduce its holdings by up to 3%, approximately 11.99 million shares [5] Group 4: Risk Matters - Yongyue Technology announced that its actual controller, Chen Xiang, has been placed under residential surveillance due to an investigation related to the disclosure of important information [6] - *ST Zitian's stock will resume trading on September 15, 2025, and enter a delisting arrangement period lasting 15 trading days, with the last trading date expected to be October 13, 2025 [7] - *ST Weier stated that there have been no significant changes in its operational situation or external environment, and no undisclosed major events exist [8]

Key Points - The article summarizes important announcements from various companies for investor reference [1] Group 1: Stock Performance and Trading - Jushen Co., Ltd. (炬申股份) experienced a stock price fluctuation with a cumulative increase of over 20% from September 10 to September 12, 2025, and is consistent with its previously disclosed share reduction plan [3] - ST Zitian (*ST紫天) will resume trading on September 15, 2025, and enter a delisting arrangement period lasting 15 trading days, with the last trading date expected to be October 13, 2025 [5] Group 2: Mergers and Acquisitions - Huibo Yuntong (慧博云通) announced that its controlling shareholder plans to acquire a total of 32.0875% of Baode Computing's shares for a total transaction price of 1.444 billion yuan, which will grant control over Baode Computing [4] Group 3: Shareholder Actions - Jifa Education (佳发教育) announced that its shareholder, De Yuan Tai, plans to reduce its stake by up to 3%, equating to 11.9854 million shares [9] - Da Yi Long (达意隆) disclosed that its shareholder, Shenzhen Lefeng Investment Management Co., Ltd., intends to reduce its stake by up to 3%, or 5.9708 million shares [10] - Multiple companies, including Pruis (普蕊斯), Wanda Information (万达信息), and Jianlong Micro-Nano (建龙微纳), reported plans for shareholders to reduce their stakes by up to 3% [11][13][14] Group 4: Operational Updates - Yongyue Technology (永悦科技) announced that its actual controller, Chen Xiang, has been released on bail pending trial due to an investigation related to information disclosure [6] - ST Tiansheng (ST天圣) received approval for its sodium bicarbonate injection to pass the consistency evaluation for generic drugs, which is used in clinical treatments [7] Group 5: Performance Metrics - Shanghai Airport (上海机场) reported that in August 2025, Pudong International Airport had a passenger throughput of 7.9471 million, a year-on-year increase of 6.9%, while Hongqiao International Airport had 4.4515 million, a 2.18% increase [20] Group 6: Contract Awards - Dashi Intelligent (达实智能) signed a contract worth 23.869 million yuan for the Xiaomi Wuhan Phase II intelligent project, which represents 0.75% of the company's audited revenue for 2024 [22]

智通财经APP讯，普蕊斯(301257.SZ)发布公告，股东上海观由投资发展有限公司观由昭泰(嘉兴)创业投 资合伙企业(有限合伙)(以下简称"观由昭泰")计划自本公告发布之日起15个交易日后的3个月内以集中竞 价交易方式和/或大宗交易方式减持公司股份不超过237.01万股(占公司总股本比例3.00%)。 ...

Group 1 - The core point of the announcement is that the shareholder, Shanghai Guanyu Investment Development Co., Ltd., plans to reduce its stake in the company by up to 2.3701 million shares, which represents 3.00% of the total share capital [1] Group 2 - The reduction of shares will occur within three months after the announcement, starting 15 trading days from the date of the announcement [1] - The shares will be sold through centralized bidding and/or block trading methods [1]

格隆汇9月14日丨普蕊斯(301257.SZ)公布，持有公司股份5,474,040股(占公司总股本比例6.93%)的股东上 海观由投资发展有限公司－观由昭泰(嘉兴)创业投资合伙企业(有限合伙)(以下简称"观由昭泰")计划自公 告发布之日起15个交易日后的3个月内以集中竞价交易方式和/或大宗交易方式减持公司股份不超过 237.01万股(占公司总股本比例3.00%)。 （原标题：普蕊斯(301257.SZ)：股东观由昭泰拟减持不超3%公司股份） ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-057 普蕊斯（上海）医药科技开发股份有限公司 关于公司持股 5%以上股东减持股份预披露公告 公司股东上海观由投资发展有限公司－观由昭泰（嘉兴）创业投资合伙企 业（有限合伙）保证向本公司提供的信息内容真实、准确、完整、没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 持有普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）股份 5,474,040 股（占本公司总股本比例 6.93%）的股东上海观由投资发展有限公司－ 观由昭泰（嘉兴）创业投资合伙企业（有限合伙）（以下简称"观由昭泰"）计划 自本公告发布之日起 15 个交易日后的 3 个月内以集中竞价交易方式和/或大宗交 易方式减持本公司股份不超过 2,370,100 股（占本公司总股本比例 3.00%）。 公司于近日收到公司股东观由昭泰出具的《股份减持计划告知函》，现将具 体事项公告如下： （以下简称"《创投减持实施细则》"），并已申请成功且通过基金业协会备案。 根据《创投减持特别规定》《创投减 ...

Group 1 - The company, Puris (301257.SZ), announced that shareholder Guanyu Zhao Tai plans to reduce its holdings by up to 2,370,100 shares, which represents 3.00% of the company's total share capital [1]

Group 1: Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [1] - The company specializes in Site Management Organization (SMO) services to enhance the quality and efficiency of clinical trials in China [2] Group 2: Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 390.10 million and a net profit of CNY 54.16 million, with a net profit excluding non-recurring items of CNY 38.54 million [2] - The second quarter of 2025 saw a year-on-year revenue growth of 1.82% and a quarter-on-quarter growth of 21.06% [2] - The net profit for the second quarter increased by 45.17% year-on-year and 528.73% quarter-on-quarter [2] Group 3: Market Demand and Contracts - The company signed new contracts worth CNY 600 million in the first half of 2025, representing a year-on-year growth of 40.12% [2] - By the end of June 2025, the company had a backlog of contracts amounting to CNY 1.99 billion, a year-on-year increase of 9.45% [2] Group 4: Project Execution and Quality Control - The company has managed over 4,000 SMO projects, with 2,428 currently active [2] - Quality control is emphasized through the establishment of over 280 standard operating procedures and continuous training for employees [5] Group 5: Industry Trends and Opportunities - The Chinese innovative drug industry is entering a new phase of high-quality development, driven by policy support and active overseas business development (BD) transactions [2] - In the first half of 2025, the number of BD transactions in China's innovative drug sector reached 72, with a total transaction value of USD 60 billion [3]

Group 1 - On September 12, two listed companies had their restricted shares unlocked, with a total market value of approximately 5.33 million yuan [1] - The specific details of the restricted share unlock are as follows: - Company "好想你" (stock code: 002582) had 110,000 shares released from equity incentive restrictions [1] - Company "普蕊斯" (stock code: 301257) had 92,500 shares released from equity incentive restrictions [1]

Core Insights - On August 29, 2023, Prasis saw a stock price increase of 20.01% with a trading volume of 278 million yuan [1] - As of August 29, 2023, Prasis had a total margin trading balance of 62.69 million yuan, which is 1.82% of its market capitalization, indicating a low financing balance compared to the past year [1] - For the first half of 2025, Prasis reported a revenue of 390 million yuan, a year-on-year decrease of 1.08%, and a net profit attributable to shareholders of 54.16 million yuan, down 1.40% year-on-year [2] Financing and Margin Trading - On August 29, 2023, Prasis had a financing buy amount of 18.66 million yuan and a financing repayment of 20.31 million yuan, resulting in a net financing buy of -1.65 million yuan [1] - The margin trading data indicates that Prasis had no short selling activity on August 29, 2023, with a short selling balance of 0.00 yuan, which is at a high level compared to the past year [1] Shareholder and Institutional Holdings - As of July 31, 2023, Prasis had 8,735 shareholders, a decrease of 7.55% from the previous period, while the average number of circulating shares per shareholder increased by 8.16% to 8,622 shares [2] - As of June 30, 2025, among the top ten circulating shareholders, Tianhong Medical Health A held 1.43 million shares, a decrease of 17,600 shares from the previous period, while Rongtong Health Industry Flexible Allocation Mixed A/B increased its holdings by 100,000 shares to 1 million shares [3]